Crown Laboratories has completed its acquisition of Revance Therapeutics, enhancing its position in the skincare industry with an expanded portfolio of innovative aesthetic and therapeutic products.

Target Information

Crown Laboratories, Inc. (“Crown”) is a privately held global leader in the skincare industry and a member of the Hildred Capital portfolio. The company is committed to delivering innovative products that cater to various skincare needs. With a strong focus on research and development, Crown has established itself as a significant player in the market, continually pushing the boundaries of skincare technology to provide effective solutions to its customers.

The recently acquired Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC) is a biotechnology company known for its innovative aesthetic and therapeutic offerings. Revance aims to set a new standard in healthcare, focusing on advanced injectables and novel delivery systems. This acquisition allows Crown to expand its capabilities and enhance its product portfolio in the fast-evolving skincare landscape.

Industry Overview

The skincare industry in the United States has witnessed substantial growth over the past few years, driven by increasing consumer awareness and a rising demand for effective skincare solutions. The market is characterized by a diverse range of products, in